F S&P 500
5,603.25 +1.00 (+0.02%) F Dow Jones
41,172.00 +26.00 (+0.06%) F Nasdaq
19,444.50 -2.75 (-0.01%) E-mini Russell 2000 Index Futur
2,137.30 +4.80 (+0.23%) Petróleo
69.34 +0.37 (+0.54%) Oro
2,589.90 +9.30 (+0.36%)
Avadel Pharmaceuticals plc (AVDL)
Fuera de horario:
Avadel Pharmaceuticals plc
10 Earlsfort Terrace
Dublin 2
Ireland
353 1 901 5201
https://www.avadel.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 154
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Gregory J. Divis Jr. | CEO & Director | 985.2k | N/D | 1967 |
| Mr. Thomas S. McHugh | Senior VP, Principal Financial and Accounting Officer & CFO | 663.14k | N/D | 1965 |
| Mr. Richard J. Kim | Chief Commercial Officer | 770.95k | N/D | 1969 |
| Mr. Jerad G. Seurer | General Counsel & Company Secretary | N/D | N/D | 1973 |
| Mr. Gregory J. Davis | VP of Corporate and Business Development | N/D | N/D | 1965 |
| Mr. Mark W. Elrod | Vice President of Sales | N/D | N/D | N/D |
| Ms. Angie Woods | Vice President of People & Culture | N/D | N/D | N/D |
| Dr. Jordan S. Dubow M.D. | Consultant | 727.93k | 395.25k | 1978 |
| Dr. Jason M. Vaughn | Senior Vice President of Technical Operations | N/D | N/D | N/D |
| Ms. Jennifer Gudeman PharmD | Senior Vice President of Medical & Clinical Affairs | N/D | N/D | N/D |
Descripción
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Gestión corporativa
La calificación ISS Governance QuickScore de Avadel Pharmaceuticals plc a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
